Last reviewed · How we verify
albuterol inhalation aerosol
Albuterol inhalation aerosol is a beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs.
Albuterol inhalation aerosol is a beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs. Used for Maintenance and relief of bronchospasm in patients with asthma and in patients with COPD.
At a glance
| Generic name | albuterol inhalation aerosol |
|---|---|
| Also known as | Proventil, Proventil-HFA |
| Sponsor | Amphastar Pharmaceuticals, Inc. |
| Drug class | Beta-2 adrenergic receptor agonist |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to beta-2 adrenergic receptors on bronchial smooth muscle cells, causing them to relax and decrease airway resistance. This results in improved lung function and relief of bronchospasm symptoms.
Approved indications
- Maintenance and relief of bronchospasm in patients with asthma and in patients with COPD
Common side effects
- Tremors
- Nervousness
- Headache
- Dizziness
- Palpitations
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (PHASE3)
- Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (PHASE3)
- Clinical Assessment of Acupuncture for the Treatment of Chronic Asthma (NA)
- Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care (PHASE4)
- National Cohort of Subjects at Risk of Developing Rheumatoid Arthritis
- A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma (PHASE3)
- BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- albuterol inhalation aerosol CI brief — competitive landscape report
- albuterol inhalation aerosol updates RSS · CI watch RSS
- Amphastar Pharmaceuticals, Inc. portfolio CI